News

Martin Lehr 8/25/21 Martin Lehr 8/25/21

Context Therapeutics® and Tyligand Bioscience Reach ONA-XR Manufacturing Optimization Milestone

Martin Lehr 5/12/21 Martin Lehr 5/12/21

Context Therapeutics® and Jefferson Health Announce First Patient Dosed in Phase 2 Trial of ONA-XR in Advanced Endometrial Cancer

Trial Will Evaluate Progesterone Receptor ONA-XR in Combination with Antiestrogen to Determine Potential of Complete Hormone Blockade on Endometrial Cancer Outcomes

Martin Lehr 4/8/21 Martin Lehr 4/8/21

Context Therapeutics and Integral Molecular Enter Collaboration and License Deal for Novel Claudin 6 Antibodies for Gynecologic Cancer Therapeutic Program